Cell Medica explores TCRs

Saturday 27 August 2016

United Kingdom

Cell Medica Ltd has strengthened its hand in the field of T cell therapy with a new collaboration around T cell receptor technology. Having recently expanded a partnership with Baylor College of Medicine in Texas, US, and acquired the Delenex Therapeutics AG antibody company in Switzerland, the company has now entered into a partnership with University College London (UCL) to develop genetically engineered T cell receptor products for cancer.